Date: 16.09.23

Your Name: Dr. Satyajeet Soni

Manuscript Title: Modified FOLFIRINOX as the first-line chemotherapy in unresectable and metastatic pancreatic

adenocarcinoma - a single-center experience in India

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

ment for expert timony  pport for attending etings and/or travel	None				
oport for attending				370	
etings and/or traver	None				
ents planned, issued or ding	None				Eva iii
ticipation on a Data ety Monitoring Board or isory Board	None				
dership or fiduciary role ther board, society, mittee or advocacy	None				
k or stock options	None				
eipt of equipment, erials, drugs, medical ng, gifts or other	None				
er financial or non- ocial interests	None				
	ding ding dicipation on a Data ety Monitoring Board or disory Board dership or fiduciary role ther board, society, mittee or advocacy up, paid or unpaid k or stock options dipt of equipment, erials, drugs, medical up, gifts or other ces r financial or non-	ding  dicipation on a Data  Ety Monitoring Board or disory Board  dership or fiduciary role ther board, society, mittee or advocacy up, paid or unpaid k or stock options  Dipt of equipment, erials, drugs, medical ng, gifts or other ces  or financial or non-  None	ding  dicipation on a Data  Ety Monitoring Board or disory Board  dership or fiduciary role ther board, society, mittee or advocacy ap, paid or unpaid k or stock options  Input of equipment, erials, drugs, medical ang, gifts or other ces  or financial or non-  None  None	ding  icicipation on a Data  Pty Monitoring Board or disory Board  dership or fiduciary role ther board, society, mittee or advocacy up, paid or unpaid k or stock options  In None  In	dicipation on a Data Sty Monitoring Board or Sisory Board Stership or fiduciary role Sther board, society, mittee or advocacy sp, paid or unpaid sk or stock options  None  Sipt of equipment, erials, drugs, medical ng, gifts or other ces r financial or non- None

Soligaziel

Date: 16.09.23

Your Name: Dr. Arpit Jain

Manuscript Title: Modified FOLFIRINOX as the first-line chemotherapy in unresectable and metastatic pancreatic

adenocarcinoma - a single-center experience in India

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initi	al planning of the work
No.	Name and Desiration	Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
.2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
3	Other financial or non- financial interests	None	

\_\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 16.09.23

Your Name: Dr. Varun Goyal

Manuscript Title: Modified FOLFIRINOX as the first-line chemotherapy in unresectable and metastatic pancreatic

adenocarcinoma - a single-center experience in India

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pas	et 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for	None	
speakers bureaus, manuscript writing or educational events		
Payment for expert testimony	None	
Support for attending meetings and/or travel	None	
Patents planned, issued or pending	None	
Participation on a Data Safety Monitoring Board or Advisory Board	None	
Leadership or fiduciary role in other board, society, committee or advocacy	None	
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
Other financial or non- financial interests	None	
ease summarize the above co	nflict of interest in the follo	owing box:
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-financial interests	lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- None

Leartify that I have answered every guestion and have not altered the wording of any of the guestion

Please place an "X" next to the following statement to indicate your agreement:

\_\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.



Date: 16.09.23

Your Name: Dr. Satya Narayan

Manuscript Title: Modified FOLFIRINOX as the first-line chemotherapy in unresectable and metastatic pancreatic

adenocarcinoma - a single-center experience in India

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
1	Stock or stock options	None	
2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
3	Other financial or non- financial interests	None	

		72. 15.1516	

\_\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 16.09.23

Your Name: Dr. Pallavi Redhu

Manuscript Title: Modified FOLFIRINOX as the first-line chemotherapy in unresectable and metastatic pancreatic

adenocarcinoma - a single-center experience in India

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for		
	lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending		
	meetings and/or travel	None	
II I			
3	Patents planned, issued or	None	
	pending		
OHE	D		
	i i i i i i i i i i i i i i i i i i i	None	
	Safety Monitoring Board or Advisory Board		
0	Leadership or fiduciary role		
	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
	Stock or stock options	None	
	Receipt of equipment,	None	
	materials, drugs, medical	ivone	
	writing, gifts or other		
	services		
	Other financial or non- financial interests	None	
	manda interests		

	Mark Taylor		
BEET.			

\_\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

P. Elha

Date: 16.09.23

Your Name: Dr. Pankaj Goyal

Manuscript Title: Modified FOLFIRINOX as the first-line chemotherapy in unresectable and metastatic pancreatic

adenocarcinoma - a single-center experience in India

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	needed) Time frame: Since the initi	
	i ime frame. Since the illit	al planning of the work
		al planning of the work
All support for the present manuscript (e.g., funding,	None	
provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		
	MARKET ELIBER	
	Time frame: pa	st 36 months
Grants or contracts from	None	
any entity (if not indicated in item #1 above).		
Royalties or licenses	None	
Consulting fees	None	
	provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	rovision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Time frame: pa  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses  None

5	Payment or have	No. of the last of	
	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
7	Patents planned, issued or pending	None	
	Participation on a Data Safety Monitoring Board or Advisory Board	None	
)	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
	Stock or stock options	None	
v	Receipt of equipment, materials, drugs, medical vriting, gifts or other ervices	None	
C fi	Other financial or non- inancial interests	None	

Please summarize the above conflict of interest in the following box:

se place on the	

Please place an "X" next to the following statement to indicate your agreement:

\_\_\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 16.09.23

Your Name: Dr. Shiva Shankara Swamy

Manuscript Title: Modified FOLFIRINOX as the first-line chemotherapy in unresectable and metastatic pancreatic

adenocarcinoma - a single-center experience in India

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
LO	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
1	Stock or stock options	None	
2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
3	Other financial or non- financial interests	None	

	TO THE STATE OF	The second			
ovt to the fell					

\_\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Sn

Date: 16.09.23

Your Name: Dr. Vineet Talwar

Manuscript Title: Modified FOLFIRINOX as the first-line chemotherapy in unresectable and metastatic pancreatic

adenocarcinoma - a single-center experience in India

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	



lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  1 Stock or stock options  1 Receipt of equipment, materials, drugs, medical writing, gifts or other services	5	Payment or honoraria for	None	
speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  1 Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- None	Fig. 13	lectures presentations	None	
manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Pattern splanned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-		speakers bureaus		
educational events  Payment for expert testimony  None  Support for attending meetings and/or travel  Pattents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-  None		manuscript writing or		
Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-  None		educational avents		
testimony  Support for attending meetings and/or travel  None  None  None  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	6			
7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-	•	tostimony	None	
meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-		testimony		
meetings and/or travel    None	7			
Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	1	Support for attending	None	
pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- None		meetings and/or travel		
pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- None				
pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- None				
pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- None				
Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	8	Patents planned issued or	N. C.	
Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- None		pending	None	
Safety Monitoring Board or Advisory Board  Deadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-				
Safety Monitoring Board or Advisory Board  Deadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	9	Participation on a Data		
Advisory Board  Deadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	Safety	Safety Monitoring Based	None	
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-		Advisory Poord		
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- None	0			
committee or advocacy group, paid or unpaid  Stock or stock options  None  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- None	Leadership or fiduciary r	Leadership or fiduciary role	None	
group, paid or unpaid  Stock or stock options  None  Receipt of equipment,  None materials, drugs, medical writing, gifts or other services  Other financial or non- None		committee and		
Stock or stock options  None  Receipt of equipment,  None  writing, gifts or other services  Other financial or non-  None		committee or advocacy		
Receipt of equipment,  None  None  None  Services		group, paid or unpaid		
materials, drugs, medical writing, gifts or other services  Other financial or non- None	1	Stock or stock options	None	THE BALL HALL COME TO SERVICE THE SERVICE
materials, drugs, medical writing, gifts or other services  Other financial or non- None				
materials, drugs, medical writing, gifts or other services  Other financial or non- None			A THE REAL PROPERTY.	
materials, drugs, medical writing, gifts or other services  Other financial or non- None		Receipt of equipment,	None	
writing, gifts or other services  3 Other financial or non-		materials, drugs, medical		
Services  Other financial or non		writing, gifts or other		
Other financial or non- financial interests  None		services		
financial interests	3	Other financial or non-	None	
		financial interests		
	3	Other financial or non-	None	
	lea	se summarize the above con	flict of interest !	
lease summarize the above conflict of interest in the second seco		The above con	inct of interest in the	following box:
lease summarize the above conflict of interest in the following box:				
lease summarize the above conflict of interest in the following box:				
lease summarize the above conflict of interest in the following box:				
lease summarize the above conflict of interest in the following box:				
lease summarize the above conflict of interest in the following box:				
lease summarize the above conflict of interest in the following box:				

\_\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.